Please assess the completion status of the following clinical trial:

Trial Title: Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC~* no previous therapy for NSCLC is allowed~* age \>18 years~* bidimensionally measurable disease~* performance status (WHO) 0-2~* absence of pleural effusion~* adequate liver (serum bilirubin \< 1.5 times the upper normal limit (UNL); AST and ALT \< 2.5 times the UNL in the absence of demonstrable liver metastases, or \< 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine \< 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* life expectancy of more than 3 months~* written informed consent~Exclusion Criteria:~* active infection~* history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* malnutrition (loss of ≥ 20% of the original body weight)~* performance status: 3-4~* sensor or motor neuropathy \> grade I~* second primary malignancy, except for non-melanoma skin cancer~* psychiatric illness or social situation that would preclude study compliance~* pregnant or lactating women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DG -\> RT
- 2 (Type: EXPERIMENTAL): DG -\> RT -\> DCarbo

Based on this trial design, predict the completion outcome and termination type (if applicable).